Abstract
Myelodysplastic syndromes (MDS) are characterized by abnormal growth of committed progenitors in clonogenic assay, with reduced number of colonies and decreased colony/cluster ratio. It has been suggested that excessive apoptosis is the cause of marrow failure in MDS. We studied the expression of caspase-1 (interleukin-1β-converting enzyme, ICE) and caspase-3 (CPP32/apopain) in marrow mononuclear cells, and the growth pattern of committed progenitors in a series of 83 MDS cases. The percentage of apoptotic cells as detected by TUNEL technique, and the percentage of caspase-3-positive cells were significantly higher in refractory anemia (RA) and RA with ringed sideroblasts (RAS) than in chronic myelomonocytic leukemia (CMML), refractory anemia with excess of blasts (RAEB) and RAEB in transformation (RAEB-T). Spontaneous growth of CFU-GM was associated with a higher percentage of blasts, and with a lower expression of caspase-3 and caspase-1. The yield of CFU-E, BFU-E, and CFU-GM (in the presence of growth factors) was decreased by comparison to normal marrow, but large individual differences were observed in all cytological categories. Inhibition of caspase-1 and caspase-3 activities by specific inhibitors resulted in a significant increase of the production of all types of colonies (up to 50-fold of control). In the presence of caspase-3 inhibitor, the number of BFU-E and CFU-E was in the range of normal values in most cases of RA and RAS. In addition, caspase-1 and -3 protease activities were detectable by fluorogenic assay in all cases studied. Western blot analysis confirmed the expression of caspase-3, including the cleaved (activated)-p17 form in most cases of RA/RAS analyzed. It is concluded that caspase-3 is implicated in the increased apoptosis observed in MDS and that inhibition of its activity can restore at least partially the growth of committed progenitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Koeffler P . Myelodysplastic syndromes (preleukemia) Semin Hematol 1986 23: 284–299
Greenberg PL . Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes Semin Hematol 1996 33: 163–175
Clark DM, Lampert IA . Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis Leuk Lymphoma 1990 2: 415–418
Yoshida Y . Apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome Leukemia 1993 7: 144–146
Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD . Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment Leukemia 1997 11: 656–659
Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H . Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes Blood 1995 86: 268–276
Raza A, Mundle S, Iftikhar A, Gregory S, Marcus B, Khan Z, Alvi S, Shetty V, Damerson S, Wright V, Adler S, Loew JM, Shott S, Ali SN, Preisler H . Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastic syndromes reveals extensive apoptosis as the probable basis for ineffective hematopoiesis Am J Hematol 1995 48: 143–154
Rajapaksa R, Ginzton N, Rott LS, Greenberg PL . Altered oncoprotein expression and apoptosis in myelodysplastic syndromemarrow cells Blood 1996 88: 4275–4287
Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P . Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol 1996 95: 368–371
Parker J, Fishlock K, Mijovic A, Czepulkowski B, Pagliuca A, Mufti G . ‘Low-risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins Br J Haematol 1998 103: 1075–1082
Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M . Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes Leukemia 1997 11: 839–845
Farrow SN, Brown R . New members of the Bcl-2 family and their protein partners Curr Opin Genet Dev 1996 6: 45–49
Reed JC . Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies Semin Hematol 1997 34: 9–19
Alnemri E, Livingstone D, Nicholson D, Salvesen G, Thornberry N, Wong W, Yuan J . Human ICE/CED-3 protease nomenclature (letter) Cell 1996 87: 171
Cohen GM . Caspases: the executioners of apoptosis Biochem J 1997 326: 1–16
Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, Elliston KO, Ayala JM, Casano RJ, Chin J, Ding GJF, Egger LA, Gaffney DP, Limjuco G, Pallyha OC, Raju SM, Rolando AM, Salley JP, Yamin TT, Lee TD, Shively JE, MacCoss M, Mumford RA, Schmidt JA, Tocci MJ . A novel heterodimeric cysteine protease is required for interleukin-1beta processing in monocytes Nature 1992 356: 768–774
Miura M, Zhu H, Rotello R, Hartwieg E, Yuan J . Induction of apoptosis in fibroblasts by IL-1beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene Ced-3 Cell 1993 75: 653–660
Fernandes-Alnemri T, Litwach G, Alnemri ES . CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme J Biol Chem 1994 269: 30761–30764
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnick YA, Munday NA, Raju SM, Smulson ME, Yamin T, Yu VL, Miller DK . Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis Nature 1995 376: 37–43
Mundle SD, Venugopal P, Cartlidge JD, Pandav DV, Broady-Robinson L, Gezer S, Robin EL, Rifkin SR, Klein M, Alston DE, Hernandez BM, Rosi D, Alvi S, Shetty VT, Gregory SA, Raza A . Indication of an involvement of Interleukin-1B converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes Blood 1996 88: 2640–2647
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C . Proposals for the classification of the myelodysplastic syndromes Br J Haematol 1982 51: 189–199
Sordet O, Bettaieb A, Bruey JM, Eymin B, Droin N, Ivarsson M, Garrido C, Solary E . Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells Cell Death Differ 1999 6: 351–361
Hasegawa JI, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda H, Tsujimoto Y . Involvement of CPP32/Yama (-like) proteases in Fas-mediated apoptosis Cancer Res 1996 56: 1713–1718
Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Archimbaud E, Vasselon C, Magaud JP, Guyotat D . High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy Blood 1993 81: 3091–3096
Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ, Hall AG . The relationship between bcl-2 expression and response to chemotherapy in acute leukemia Br J Haematol 1994 88: 105–109
Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G . Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia Leukemia 1995 9: 1191–1198
Lepelley P, Soenen V, Preudhomme C, Merlat A, Cosson A, Fenaux P . Bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis Leukemia 1995 9: 726–730
Davis R, Greenberg P . Bcl-2 expression by myelois precursors in myelodysplastic syndromes: relation to disease progression Leuk Res 1998 22: 767–777
Bradbury DA, Zhu YM, Russell NH . Bcl-2 expression in acute myeloid leukemia: relationship with autonomous growth and CD34 antigen expression Leukemia 1997 24: 221–228
Mundle SD, Mativi BY, Bagai K, Feldman G, Cheema P, Gautam U, Reza S, Cartlidge JD, Venugopal P, Shetty V, Gregory SA, Robin E, Rifkin S, Shah R, Raza A . Spontaneous down-regulation of Fas associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows Int J Hematol 1999 70: 83–90
Margolin N, Raybuck SA, Wilson KP, Chen W, Fox T, Gu Y, Livingston DJ . Substrate and inhibitor specificity of interleukin-1 beta converting enzyme and related caspases J Biol Chem 1997 272: 7223–7228
Bouscary D, Chen YL, Guesnu M, Picard F, Viguier F, Lacombe C, Dreyfus F, Fontenay-Roupie M . Activity of the caspase-3/CPP32 enzyme is increased in ‘early stage’ myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro Exp Hematol 2000 28: 784–791
Acknowledgements
This work was supported by a grant from Comité Départemental de la Lutte contre le Cancer de la Loire.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boudard, D., Sordet, O., Vasselon, C. et al. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. Leukemia 14, 2045–2051 (2000). https://doi.org/10.1038/sj.leu.2401959
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401959
Keywords
This article is cited by
-
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study
Journal of Hematology & Oncology (2012)
-
Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia
Apoptosis (2008)
-
Myelodysplastic syndromes: the complexity of stem-cell diseases
Nature Reviews Cancer (2007)
-
Survivin expression in “low-risk” and “high-risk” myelodysplastic syndromes
Annals of Hematology (2007)
-
Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia
Leukemia (2003)